Myriad Genetics Inc
Suletud
SektorTervishoid
3.06 -1.92
Ülevaade
Aktsiahinna muutus
24h
Min
3.03
Max
3.25
Sissetulek | -9.1M -43M |
|---|---|
Müük | -9.7M 191M |
Aktsiakasum | -0.33 |
Kasumimarginaal | -22.653 |
Töötajad | 2,700 |
EBITDA | -21M -39M |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | +81.07% upside |
Järgmine tulemuste avaldamine | 2. nov 2026 |
|---|
Turukapital | -230M 285M |
|---|---|
Eelmine avamishind | 4.98 |
Eelmine sulgemishind | 3.06 |
Myriad Genetics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Myriad Genetics Inc Prognoos
Hinnasiht
By TipRanks
81.07% tõus
12 kuu keskmine prognoos
Keskmine 5.74 USD 81.07%
Kõrge 10 USD
Madal 3 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Myriad Genetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
